Policy | February 02, 2024
Industry’s reaction to Union Budget 2024-25
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The inspection of the facility conducted from August 7 to August 11, 2023
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Subscribe To Our Newsletter & Stay Updated
